In the obesity landscape, glucagoon-like peptide-1 (GLP-1) agonists dominate the weight loss market. Amylin agonists work differently from GLP-1s but may be able to induce similar weight loss with fewer adverse events. My client wanted to understand the molecular differences between various amylin assets and their hypothetical impacts on the efficacy / adverse event profile. […]
Archive for April 18th, 2024
Current research on drug used for obesity and weight loss
Posted by Michael A. S. Guth on April 18th, 2024